Roflumilast cream significantly reduces itch in chronic plaque psoriasis

Arcutis Biotherapeutics announced positive results from two pivotal phase 3 studies evaluating Zoryve cream as a once daily, topic treatment for chronic plaque psoriasis, according to a company press release.
The results evaluating Zoryve (roflumilast cream 0.3%), a nonsteroid, phosphodiesterase-4 inhibitor, were published in The Journal of the American Medical Association.
“Itch is the symptom that psoriasis patients identify as the main driver of their disease severity, so it is important for any psoriasis therapy to control this symptom,” Patrick Burnett MD, PhD, FAAD, Chief

Arcutis Biotherapeutics announced positive results from two pivotal phase 3 studies evaluating Zoryve cream as a once daily, topic treatment for chronic plaque psoriasis, according to a company press release.
The results evaluating Zoryve (roflumilast cream 0.3%), a nonsteroid, phosphodiesterase-4 inhibitor, were published in The Journal of the American Medical Association.
“Itch is the symptom that psoriasis patients identify as the main driver of their disease severity, so it is important for any psoriasis therapy to control this symptom,” Patrick Burnett MD, PhD, FAAD, Chief